融創(01918.HK)一筆昆明文旅城項目ABS未足額兌付 據報計劃展期方案
據《澎湃新聞》從債權人處了解到,融創中國(01918.HK)旗下申萬宏源-融創昆明文旅城資產支持專項計劃第五次應付信託標的債權本息未償付,總計金額約4,663.36萬元人民幣。
報道指,融創房地產擬安排下屬公司聘請雲南路達會計師事務所有限公司對標的物業進行專項審計工作,對運行以來的成本營運數據進行審計,以便於盡快形成具體後續展期方案,將在近期召開會議以審議方案。
該筆信託標的債權(ABS)成立於2021年7月12日,發行規模23億元人民幣,預期到期日2033年1月30日,借款人為昆明融創城投資有限公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.